Publication

The comparative evidence basis for the efficacy of second-generation antidepressants in the treatment of depression in the US: A Bayesian meta-analysis of Food and Drug Administration reviews

Monden, R., Roest, A. M., van Ravenzwaaij, D., Wagenmakers, E-J., Morey, R., Wardenaar, K. J. & de Jonge, P., 1-Aug-2018, In : Journal of Affective Disorders. 235, p. 393-398 6 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Monden, R., Roest, A. M., van Ravenzwaaij, D., Wagenmakers, E-J., Morey, R., Wardenaar, K. J., & de Jonge, P. (2018). The comparative evidence basis for the efficacy of second-generation antidepressants in the treatment of depression in the US: A Bayesian meta-analysis of Food and Drug Administration reviews. Journal of Affective Disorders, 235, 393-398. https://doi.org/10.1016/j.jad.2018.04.040

Author

Monden, Rei ; Roest, Annelieke M ; van Ravenzwaaij, Don ; Wagenmakers, Eric-Jan ; Morey, Richard ; Wardenaar, Klaas J ; de Jonge, Peter. / The comparative evidence basis for the efficacy of second-generation antidepressants in the treatment of depression in the US : A Bayesian meta-analysis of Food and Drug Administration reviews. In: Journal of Affective Disorders. 2018 ; Vol. 235. pp. 393-398.

Harvard

Monden, R, Roest, AM, van Ravenzwaaij, D, Wagenmakers, E-J, Morey, R, Wardenaar, KJ & de Jonge, P 2018, 'The comparative evidence basis for the efficacy of second-generation antidepressants in the treatment of depression in the US: A Bayesian meta-analysis of Food and Drug Administration reviews', Journal of Affective Disorders, vol. 235, pp. 393-398. https://doi.org/10.1016/j.jad.2018.04.040

Standard

The comparative evidence basis for the efficacy of second-generation antidepressants in the treatment of depression in the US : A Bayesian meta-analysis of Food and Drug Administration reviews. / Monden, Rei; Roest, Annelieke M; van Ravenzwaaij, Don; Wagenmakers, Eric-Jan; Morey, Richard; Wardenaar, Klaas J; de Jonge, Peter.

In: Journal of Affective Disorders, Vol. 235, 01.08.2018, p. 393-398.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Monden R, Roest AM, van Ravenzwaaij D, Wagenmakers E-J, Morey R, Wardenaar KJ et al. The comparative evidence basis for the efficacy of second-generation antidepressants in the treatment of depression in the US: A Bayesian meta-analysis of Food and Drug Administration reviews. Journal of Affective Disorders. 2018 Aug 1;235:393-398. https://doi.org/10.1016/j.jad.2018.04.040


BibTeX

@article{842b1441d0f34797b95b3a6a72262150,
title = "The comparative evidence basis for the efficacy of second-generation antidepressants in the treatment of depression in the US: A Bayesian meta-analysis of Food and Drug Administration reviews",
abstract = "BACKGROUND: Studies have shown similar efficacy of different antidepressants in the treatment of depression.METHOD: Data of phase-2 and -3 clinical-trials for 16 antidepressants (levomilnacipran, desvenlafaxine, duloxetine, venlafaxine, paroxetine, escitalopram, vortioxetine, mirtazapine, venlafaxine XR, sertraline, fluoxetine, citalopram, paroxetine CR, nefazodone, bupropion, vilazodone), approved by the FDA for the treatment of depression between 1987 and 2016, were extracted from the FDA reviews that were used to evaluate efficacy prior to marketing approval, which are less liable to reporting biases. Meta-analytic Bayes factors, which quantify the strength of evidence for efficacy, were calculated. In addition, posterior pooled effect-sizes were calculated and compared with classical estimations.RESULTS: The resulted Bayes factors showed that the evidence load for efficacy varied strongly across antidepressants. However, all tested drugs except for bupropion and vilazodone showed strong evidence for their efficacy. The posterior effect-size distributions showed variation across antidepressants, with the highest pooled estimated effect size for venlafaxine followed by paroxetine, and the lowest for bupropion and vilazodone.LIMITATIONS: Not all published trials were included in the study.CONCLUSIONS: The results illustrate the importance of considering both the effect size and the evidence-load when judging the efficacy of a treatment. In doing so, the currently employed Bayesian approach provided clear insights on top of those gained with traditional approaches.",
keywords = "Food and Drug Administration (FDA), Depression, Antidepressant, Bayes factor, Bayesian statistics, SUBSTANCE USE DISORDERS, CONFIDENCE-INTERVALS, MEDICAL STATISTICS, ANXIETY DISORDERS, CLINICAL-TRIALS, GLOBAL BURDEN, PRIMARY-CARE, DISABILITY, BUPROPION, DISEASE",
author = "Rei Monden and Roest, {Annelieke M} and {van Ravenzwaaij}, Don and Eric-Jan Wagenmakers and Richard Morey and Wardenaar, {Klaas J} and {de Jonge}, Peter",
note = "Copyright {\circledC} 2018 Elsevier B.V. All rights reserved.",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.jad.2018.04.040",
language = "English",
volume = "235",
pages = "393--398",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "ELSEVIER SCIENCE BV",

}

RIS

TY - JOUR

T1 - The comparative evidence basis for the efficacy of second-generation antidepressants in the treatment of depression in the US

T2 - A Bayesian meta-analysis of Food and Drug Administration reviews

AU - Monden, Rei

AU - Roest, Annelieke M

AU - van Ravenzwaaij, Don

AU - Wagenmakers, Eric-Jan

AU - Morey, Richard

AU - Wardenaar, Klaas J

AU - de Jonge, Peter

N1 - Copyright © 2018 Elsevier B.V. All rights reserved.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - BACKGROUND: Studies have shown similar efficacy of different antidepressants in the treatment of depression.METHOD: Data of phase-2 and -3 clinical-trials for 16 antidepressants (levomilnacipran, desvenlafaxine, duloxetine, venlafaxine, paroxetine, escitalopram, vortioxetine, mirtazapine, venlafaxine XR, sertraline, fluoxetine, citalopram, paroxetine CR, nefazodone, bupropion, vilazodone), approved by the FDA for the treatment of depression between 1987 and 2016, were extracted from the FDA reviews that were used to evaluate efficacy prior to marketing approval, which are less liable to reporting biases. Meta-analytic Bayes factors, which quantify the strength of evidence for efficacy, were calculated. In addition, posterior pooled effect-sizes were calculated and compared with classical estimations.RESULTS: The resulted Bayes factors showed that the evidence load for efficacy varied strongly across antidepressants. However, all tested drugs except for bupropion and vilazodone showed strong evidence for their efficacy. The posterior effect-size distributions showed variation across antidepressants, with the highest pooled estimated effect size for venlafaxine followed by paroxetine, and the lowest for bupropion and vilazodone.LIMITATIONS: Not all published trials were included in the study.CONCLUSIONS: The results illustrate the importance of considering both the effect size and the evidence-load when judging the efficacy of a treatment. In doing so, the currently employed Bayesian approach provided clear insights on top of those gained with traditional approaches.

AB - BACKGROUND: Studies have shown similar efficacy of different antidepressants in the treatment of depression.METHOD: Data of phase-2 and -3 clinical-trials for 16 antidepressants (levomilnacipran, desvenlafaxine, duloxetine, venlafaxine, paroxetine, escitalopram, vortioxetine, mirtazapine, venlafaxine XR, sertraline, fluoxetine, citalopram, paroxetine CR, nefazodone, bupropion, vilazodone), approved by the FDA for the treatment of depression between 1987 and 2016, were extracted from the FDA reviews that were used to evaluate efficacy prior to marketing approval, which are less liable to reporting biases. Meta-analytic Bayes factors, which quantify the strength of evidence for efficacy, were calculated. In addition, posterior pooled effect-sizes were calculated and compared with classical estimations.RESULTS: The resulted Bayes factors showed that the evidence load for efficacy varied strongly across antidepressants. However, all tested drugs except for bupropion and vilazodone showed strong evidence for their efficacy. The posterior effect-size distributions showed variation across antidepressants, with the highest pooled estimated effect size for venlafaxine followed by paroxetine, and the lowest for bupropion and vilazodone.LIMITATIONS: Not all published trials were included in the study.CONCLUSIONS: The results illustrate the importance of considering both the effect size and the evidence-load when judging the efficacy of a treatment. In doing so, the currently employed Bayesian approach provided clear insights on top of those gained with traditional approaches.

KW - Food and Drug Administration (FDA)

KW - Depression

KW - Antidepressant

KW - Bayes factor

KW - Bayesian statistics

KW - SUBSTANCE USE DISORDERS

KW - CONFIDENCE-INTERVALS

KW - MEDICAL STATISTICS

KW - ANXIETY DISORDERS

KW - CLINICAL-TRIALS

KW - GLOBAL BURDEN

KW - PRIMARY-CARE

KW - DISABILITY

KW - BUPROPION

KW - DISEASE

U2 - 10.1016/j.jad.2018.04.040

DO - 10.1016/j.jad.2018.04.040

M3 - Article

VL - 235

SP - 393

EP - 398

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

ER -

ID: 58261696